Sun Pharmaceutical Industries Ltd News

NSE breaks into top 10 BSE market-cap league on debut; beats HUL, Titan

NSE's market capitalisation increased to ₹4.62 trillion to reach 10th position on the BSE, following a 5% rise in Thursday's debut trading session; beating HUL, Sun Pharma and Titan in ranking.

Pharma stocks zoom: Laurus Labs, Aurobindo hit new highs in trade

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

Stocks to watch: ICICI Pru AMC, Meesho, Wipro, Shakti Pumps, Hindustan Zinc

Stocks to watch: ICICI Pru AMC, Meesho, Wipro, Shakti Pumps, Hindustan Zinc, Sun Pharma, Bank of Baroda, Axis Bank, MCX, among others, will be in focus today.

Stocks to watch: Sun Pharma, Suzlon Energy, OMCs, Biocon, IHCL, Tata Power

Stocks to watch: Sun Pharma, Suzlon Energy, OMCs, Biocon, IHCL, Tata Power, TCS, Jio Financial Services, HCL Technologies, Emami Ltd, Bajaj Finance, among others, will be in focus today.

Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries -- India's largest pharmaceutical company -- over the proposed USD 11.75-billion acquisition of US-based Organon & Co. S&P Global Ratings assigned a preliminary 'BBB+' long-term issuer credit rating, while Moody's Ratings assigned a 'Baa1' long-term issuer rating to the Indian pharmaceutical major. Both agencies have maintained a 'stable' outlook for the company. Baa1 and BBB+ are investment-grade credit ratings that indicate adequate payment capacity with moderate credit risk. The rating actions follow Sun Pharma's binding bid in April 2026 to acquire a 100 per cent stake in Organon for an enterprise value of USD 11.75 billion. The transaction is expected to close by March 2027, subject to regulatory approvals. According to S&P, the acquisition will bolster Sun Pharma's business position, almost doubling its revenue base to about Rs 1.3 trillion (around USD 14 billion) ..

Sun Pharma signs US deal to offer 'most favoured nation' pricing on drugs

Sun Pharmaceutical Industries on Tuesday announced it has entered into an agreement with the US government to prioritise access to affordable medicines for American patients. As part of the agreement, signed during a ceremony at the White House, Mumbai-based Sun Pharma, India's largest drugmaker, will extend 'Most Favoured Nation' (MFN) pricing to state Medicaid programmes, the company said in a regulatory filing on Tuesday. The commitment to MFN pricing will also apply to Sun Pharma's future innovative medicine launches in the US market, the filing said. MFN pricing generally ensures that a buyer receives the lowest price available for a drug. The agreement, which was signed alongside several other pharmaceutical companies, recognises Sun Pharma's investment in the US by delaying Section 232 tariffs on its innovative pharmaceutical products for over two years. The company did not disclose other terms of the deal. "The United States is a key area of investment and expansion for Su

F&O: Nifty sees healthy rollovers; eyes triangle breakout in Sep series

The Nifty August expiry delivered the most constructive positioning setup in four months, with improving rollover, rising carry and broader sectoral leadership, says Systematix in its F&O report.

Sun Pharma Q1 profit rises 27%; US generics remain under pressure

Sun Pharma reported a 27 per cent rise in Q1FY27 profit, driven by India and innovative medicines, while weakness in the US generics business continued to weigh on growth

Healthcare up for 4th straight month; Divis, Laurus, Torrent at new highs

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.

Sun Pharma Q1 profit rises 27% to ₹2,895 crore as revenue grows over 10%

Revenue from operations grew 10.5 per cent to ₹15,299.88 crore, while EBITDA margin narrowed by 220 basis points to 28.9 per cent as India sales rose 16 per cent

Stocks to Watch today: Tata Steel, ITC, Sun Pharma, Swiggy, IOCL, IRFC

Stocks to watch today: Tata Steel, Tata Power, ITC, Sun Pharma, Swiggy, IOCL, IRFC, Maruti Suzuki, Bajaj Finance, JBM Auto, LIC Housing Finance, Hyundai Motor, among others, will be in focus today

Sun Pharma, TVS Motor, Nestle, Divis among 11 BSE 500 stocks at new highs

Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.

Sun Pharma to launch semaglutide in Brazil with Hypera Pharma soon

Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market

Sun Pharma Q1 preview: Robust domestic growth to drive revenue by 11% Y-o-Y

Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.

Sun Pharma: Bajaj Broking recommends 'Buy'; flags 4 positive cues on charts

Sun Pharma outlook: Analysts at Bajaj Broking flag a breakout above the monthly consolidation zone and the formation of higher-highs, higher-lows among key reasons for a bullish view on the stock.

The reform booster shot that transformed India into pharmacy of the world

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5%

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

Sun Pharma gets South Africa approval for generic semaglutide, launch soon

Sun Pharma has secured South Africa's approval for its generic semaglutide injection and plans to launch the once-weekly diabetes treatment in the coming days

Sun Pharma receives approval to launch generic semaglutide in South Africa

The approval makes South Africa the second market after India where the drugmaker has secured regulatory clearance for its generic version of semaglutide